Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
💊
Prescription Drugs
💊 Drugs • 11,927 recalls
Class I - Dangerous
Packaging defect: observed packaging defect, blister packaging inadequately sealed.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
Subpotent Drug
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
Norepinephrine Bitartrate in 0.9% Sodium Chloride Injection, USP, 8 mg/250 mL (32 mcg/mL*), 250 mL Single-Dose Container, packaged in 15 x 1 IV Bottles per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC 69374-316-25.
Nephron Sterile Compounding Center
Class I - Dangerous
Lack of Assurance of Sterility
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.
Class I - Dangerous
CGMP Deviations: recalling drug products following an FDA inspection.